Compare HTGC & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTGC | TARS |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | 50 | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | N/A | 2020 |
| Metric | HTGC | TARS |
|---|---|---|
| Price | $15.46 | $62.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $18.86 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.4M | 462.7K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 12.13% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $11.18 | $56.43 |
| Revenue Next Year | $5.24 | $30.19 |
| P/E Ratio | $8.61 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $13.70 | $38.51 |
| 52 Week High | $19.67 | $85.25 |
| Indicator | HTGC | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 54.47 |
| Support Level | $15.22 | $61.24 |
| Resistance Level | $15.96 | $66.36 |
| Average True Range (ATR) | 0.28 | 2.68 |
| MACD | 0.01 | 0.48 |
| Stochastic Oscillator | 54.35 | 81.96 |
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.